Literature DB >> 26622823

Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature.

Arife Ulas1, Kamile Silay2, Sema Akinci3, Muhammed Bulent Akinci4, Mehmet Ali Sendur4, Didem Sener Dede4, Yunus Halil Polat5, Bulent Yalcin4.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy that is characterized by microvascular thrombosis, thrombocytopenia, hemolysis and end organ damage. An extensive variety of drugs, including certain chemotherapeutic agents, have been associated with TTP. However, paclitaxel, cisplatin and ifosfamide regimen (TIP)-induced TTP has not previously been described. The present study reports the case of a 43-year-old patient with a refractory testicular germ cell tumor who developed acute TTP during TIP chemotherapy. Following the third cycle of TIP chemotherapy, the patient developed fever, anemia, thrombocytopenia and confusion. A diagnosis of TTP was established. Plasmapheresis was initiated as daily treatment in the first week, then continued every other day for 4 weeks. TIP chemotherapy was discontinued. The patient's clinical and neurological symptoms improved markedly after a week. Renal function and hemolysis improved, and the patient was discharged in a stable condition. The patient did not develop any complications and has been in remission for 5 months. The Naranjo adverse drug reaction probability scale indicated a likely association between TTP and the TIP chemotherapy regimen in this patient. This case is also investigated with regard to the associated literature to increase the awareness of TTP following chemotherapy.

Entities:  

Keywords:  cisplatin; ifosphamide; paclitaxel; thrombotic microangiopathy; thrombotic thrombocytopenic purpura

Year:  2015        PMID: 26622823      PMCID: PMC4579812          DOI: 10.3892/ol.2015.3338

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient.

Authors:  L I Gordon; H C Kwaan
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

3.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

Review 4.  Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

Review 5.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

6.  Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.

Authors:  Yu Nishijima; Haruhiko Hirata; Aiko Himeno; Hiroshi Kida; Masanori Matsumoto; Ryo Takahashi; Yasushi Otani; Kouji Inoue; Izumi Nagatomo; Yoshito Takeda; Takashi Kijima; Isao Tachibana; Yoshihiro Fujimura; Atsushi Kumanogoh
Journal:  Intern Med       Date:  2013-05-15       Impact factor: 1.271

Review 7.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

8.  Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.

Authors:  J E Cantrell; T M Phillips; P S Schein
Journal:  J Clin Oncol       Date:  1985-05       Impact factor: 44.544

9.  Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.

Authors:  Wade Iams; Kathyrn Eby Beckermann; Anne T Neff; Ingrid A Mayer; Vandana Gupta Abramson
Journal:  Med Oncol       Date:  2013-04-07       Impact factor: 3.064

10.  Thrombotic thrombocytopenic purpura and gemcitabine.

Authors:  Pashtoon Murtaza Kasi
Journal:  Case Rep Oncol       Date:  2011-03-16
View more
  1 in total

1.  An Update in Drug-Induced Thrombotic Microangiopathy.

Authors:  Thomas Chatzikonstantinou; Maria Gavriilaki; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  Front Med (Lausanne)       Date:  2020-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.